10-K: Acutus Medical Shifts Focus to Manufacturing, Restructures Operations

Sentiment:

Annual Results 1 April 2024 4:19 PM

Acutus Medical is restructuring its business to focus solely on manufacturing left-heart access products for Medtronic, discontinuing its mapping and ablation businesses.

Delay expectedThe company expects the Restructuring to be substantially complete in the first quarter of 2024, which is a delay from the original plan.

Capital raiseThe company may need to raise additional capital to fund its operations.Such additional funding is not likely to be available on acceptable terms, or at all.

Worse than expectedThe company's net loss from continuing operations was $11.9 million for 2023, compared to a net income of $28.8 million in 2022.The company is now entirely dependent on a single customer, Medtronic, for revenue.The company is winding down its mapping and ablation businesses, which were previously a core part of its operations.

Summary

Acutus Medical is undergoing a strategic restructuring, shifting its focus to manufacturing left-heart access products for Medtronic.
The company is winding down its mapping and ablation businesses, including the AcQMap system, and will no longer manufacture or distribute these products.
This restructuring involves a workforce reduction of approximately 160 employees, about 65% of the total workforce.
Acutus will now rely solely on its partnership with Medtronic for revenue, through manufacturing and potential earnout payments.
The company completed the sale of its left-heart access portfolio to Medtronic in 2022 for $50 million upfront, plus potential earnouts.
Acutus has already received $37 million in contingent cash consideration related to the sale.
The company is eligible for additional earnout payments based on Medtronic's net sales of the left-heart access products through 2027.
In 2023, Acutus earned $9.4 million related to the Net Sales Earnouts, with $7.3 million paid in January 2024.
The company has recognized $18.6 million of the estimated $21.0 million to $32.0 million of pre-tax restructuring and exit-related charges as of December 31, 2023.
Acutus had a net loss of $11.9 million from continuing operations for the year ended December 31, 2023.

Sentiment

Score: 3

Explanation: The document indicates a significant strategic shift and restructuring due to financial challenges, with a high reliance on a single customer and a history of losses. While there are potential positives, the overall outlook is uncertain and carries substantial risks.

Positives

The company has secured a strategic partnership with Medtronic for manufacturing.
Acutus has already received $37 million in contingent cash consideration related to the sale of its left-heart access portfolio.
The company is eligible for additional earnout payments based on Medtronic's net sales through 2027.
The restructuring is expected to reduce operating expenses and optimize cash resources.

Negatives

Acutus is now completely dependent on Medtronic for revenue.
The company is discontinuing its mapping and ablation businesses, which were previously a core part of its operations.
The restructuring involves a significant workforce reduction.
The company has incurred significant losses since its inception.
There are continued risks associated with the Restructuring, including the ability to complete the wind down and to manage the associated Restructuring and transition costs to realize the anticipated benefits.

Risks

The company is now entirely dependent on Medtronic for revenue, and the loss of this partnership would eliminate revenue.
The company's business is not diversified, making it vulnerable to disruptions in its sole business line.
If the distribution agreement with Medtronic terminates, Acutus will have no sources of revenue.
There are risks associated with the restructuring, including the ability to manage costs and maintain relationships with employees and vendors.
The company's ability to service its debt and fund operations depends on generating sufficient cash flow or obtaining other financing.
If the restructuring is not successful, the board may decide to pursue liquidation and dissolution of the business.
The commercial success of the products depends on market acceptance among hospitals, physicians, patients, and payors.
The company operates in a highly competitive industry and faces competition from Medtronic itself.
The company depends on third-party suppliers, including single-source suppliers, making it vulnerable to supply disruptions and price fluctuations.
Defects or failures associated with the products could lead to recalls, safety alerts, or litigation.
The company is operating in a period of economic uncertainty and capital markets disruption.
Failure to maintain compliance with Nasdaq's continued listing requirements would result in the delisting of the company's common stock.

Future Outlook

Acutus expects to rely solely on its strategic partnership with Medtronic to generate revenue through manufacturing and potential earnout payments. The company plans to focus on efficient manufacturing, high quality, and reliability to capture manufacturing demands from Medtronic.

Management Comments

The board of directors determined to reallocate capital from the mapping and ablation business to the manufacturing of left-heart access products for Medtronic.
The company believes this will maximize the potential for future contingent cash consideration and cash flow.

Industry Context

The medical device industry is intensely competitive, subject to rapid change, and significantly affected by new product introductions. Acutus is now competing with contract manufacturers of cardiovascular medical devices and indirectly with Medtronic's competitors in the electrophysiology field.

Comparison to Industry Standards

Acutus's shift to contract manufacturing is a departure from its previous business model of developing and marketing its own products, which is more common in the medical device industry.
The company's reliance on a single customer, Medtronic, is a significant risk compared to companies with diversified customer bases.
The restructuring and workforce reduction are drastic measures, indicating the company's financial challenges and strategic shift.
The company's financial performance, with significant losses and reliance on earnouts, is not typical of established medical device companies.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Senior Vice President, Chief People Officer	Charlie Piscitello		2023-07-14	Departure
President and Chief Executive Officer	David Roman	Takeo Mukai	2024-01-07	Departure
Senior Vice President, Commercial	Kevin Mathews		2024-01-07	Departure
Chief Administrative Officer, General Counsel and Secretary	Tom Sohn		2024-02-06	Departure

Legal Proceedings

The company and certain officers are defendants in two putative securities class action lawsuits.
Biotronik has filed a Demand for Arbitration against Acutus, alleging breach of contract and seeking $38 million in damages.

Related Party Transactions

The company has a consulting agreement with the chairman of the board.
The company has a credit agreement with related parties Deerfield Private Design Fund III, L.P. and Deerfield Partners, L.P.

Stakeholder Impact

Shareholders face the risk of losing their investment if the restructuring is not successful.
Employees have been impacted by a significant workforce reduction.
Customers of the mapping and ablation products will no longer have access to those products.
Medtronic is now the sole customer for Acutus's manufacturing business.
Suppliers may be affected by the change in Acutus's business model.

Next Steps

Complete the restructuring process in the first quarter of 2024.
Focus on manufacturing improvements and efficient production for Medtronic.
Explore strategic alternatives for the mapping and ablation businesses.
Continue to monitor the closing bid price of the common stock and the potential delisting from Nasdaq.

Key Dates

Date	Description
2011-03-25	Acutus Medical, Inc. was incorporated in Delaware.
2019-06-12	Date of the Investors Rights Agreement.
2019-06-30	Date of the 2019 credit agreement.
2021-08-23	Date of the issuance of Series A Common Stock Equivalent Convertible Preferred Stock.
2022-04-26	Date of the Asset Purchase Agreement with Medtronic.
2022-06-30	Date of the First Closing of the sale of the left-heart access portfolio to Medtronic and the 2022 Credit Agreement.
2022-10-31	Date the OEM Earnout was achieved.
2022-12-31	Date the Transfer Earnout was achieved.
2023-08-04	Date of Amendment No. 1 to the 2022 Credit Agreement.
2023-11-08	Date of the announcement of the strategic realignment and restructuring and Amendment No. 2 to the 2022 Credit Agreement.
2024-02-16	Date the Biotronik Parties filed the Demand against Acutus with the American Arbitration Association.
2024-03-04	Date of Amendment No. 3 to the 2022 Credit Agreement.
2024-04-29	Expected date of delisting from Nasdaq.

Keywords

Acutus Medical, Medtronic, left-heart access, manufacturing, restructuring, electrophysiology, cardiovascular, medical devices, contract manufacturing, distribution agreement

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.